BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M, Liu MY. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness. World J Gastrointest Oncol 2022; 14(4): 920-934 [PMID: 35582108 DOI: 10.4251/wjgo.v14.i4.920]
URL: https://www.wjgnet.com/1948-5182/full/v14/i4/920.htm
Number Citing Articles
AntineoplasticsReactions Weekly 2022; 1913(1): 61 doi: 10.1007/s40278-022-18211-x